ArQule (ARQL) Upgraded at ValuEngine

ArQule (NASDAQ:ARQL) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Thursday, March 15th.

Other analysts have also issued research reports about the company. Needham & Company LLC raised ArQule from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th. Zacks Investment Research raised ArQule from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a research note on Wednesday, November 15th. Roth Capital began coverage on ArQule in a research note on Thursday, February 22nd. They issued a “buy” rating and a $5.00 price target on the stock. Finally, B. Riley set a $3.00 price target on ArQule and gave the stock a “buy” rating in a research note on Thursday, February 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. ArQule presently has a consensus rating of “Buy” and a consensus price target of $4.08.

How to Become a New Pot Stock Millionaire

Shares of ARQL traded down $0.10 during trading hours on Thursday, reaching $2.85. 1,367,252 shares of the company traded hands, compared to its average volume of 1,396,302. The company has a quick ratio of 4.98, a current ratio of 4.98 and a debt-to-equity ratio of 1.03. The firm has a market cap of $248.26, a P/E ratio of -7.31 and a beta of 0.83. ArQule has a fifty-two week low of $0.92 and a fifty-two week high of $3.35.

ArQule (NASDAQ:ARQL) last posted its quarterly earnings data on Monday, March 5th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). During the same period last year, the business posted ($0.10) EPS. equities analysts expect that ArQule will post -0.31 EPS for the current fiscal year.

In other ArQule news, insider Value Fund L. P. Biotechnology sold 2,301,581 shares of the firm’s stock in a transaction dated Wednesday, April 4th. The stock was sold at an average price of $2.90, for a total value of $6,674,584.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.00% of the stock is currently owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new position in shares of ArQule in the 3rd quarter worth about $2,220,000. BVF Inc. IL raised its holdings in shares of ArQule by 122.1% in the 4th quarter. BVF Inc. IL now owns 16,436,912 shares of the biotechnology company’s stock worth $27,121,000 after purchasing an additional 9,036,784 shares during the period. Virtu Financial LLC raised its holdings in shares of ArQule by 343.8% in the 4th quarter. Virtu Financial LLC now owns 129,038 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 99,964 shares during the period. Northern Trust Corp raised its holdings in shares of ArQule by 0.9% in the 2nd quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 1,385 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of ArQule in the 4th quarter worth about $165,000. Institutional investors own 67.08% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/arqule-arql-rating-increased-to-hold-at-valuengine.html.

ArQule Company Profile

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply